Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
58,000,000
-
Total 13F shares
-
47,903,925
-
Share change
-
-1,358,107
-
Total reported value
-
$102,516,125
-
Put/Call ratio
-
2393%
-
Price per share
-
$2.14
-
Number of holders
-
85
-
Value change
-
-$13,785,684
-
Number of buys
-
48
-
Number of sells
-
44
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) as of Q4 2024
As of 31 Dec 2024,
Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
47,903,925 shares.
The largest 10 holders included
T. Rowe Price Investment Management, Inc., Bellevue Group AG, Vestal Point Capital, LP, NEA Management Company, LLC, BlackRock, Inc., VANGUARD GROUP INC, TANG CAPITAL MANAGEMENT LLC, Siren, L.L.C., GEODE CAPITAL MANAGEMENT, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
85
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.